[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100464697":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":20,"responsibleParty":39,"collaborators":7,"id":41,"slug":7,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":50,"targetDuration":7,"studyType":53,"phases":7,"briefSummary":54,"conditions":55,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Samra Turajlic","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Laura Boddy","CONTACT","020 7352 8171","exact@rmh.nhs.uk",{"name":19,"role":15,"phone":7,"phoneExt":7,"email":17},"Arjun Modi",[21],{"facility":5,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Chelsea","London","SW3 6JJ","United Kingdom","UK",{"type":29,"coordinates":30},"Point",[31,32],-0.16936,51.48755,{"lat":32,"lon":31},[35],{"name":36,"role":15,"phone":37,"phoneExt":7,"email":38},"Dilruba Kabir","02073528171","dilruba.kabir@rmh.nhs.uk",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100464697",false,"NCT05331066","Understanding immunE-related toXicities by multifACeT Profiling","EXACT - Understanding immunE-related toXicities by multifACeT Profiling","EXACT","Inclusion Criteria:\n\n* Written informed consent\n* Age 18 years or older\n* Confirmed diagnosis of any form of solid malignancy with a clinical indication and appropriate treatment plan to commence immune checkpoint inhibitor therapy\n\nExclusion Criteria:\n\n* Medical or psychological condition that would preclude informed consent\n* Planned participation in a drug trial receiving investigational agents\n* Subjects who have previously commenced immune checkpoint inhibitor therapy prior to study entry.\n* Subjects unable to comply with the study or sample schedule.","ALL","18 Years",{"count":51,"type":52},200,"ESTIMATED","OBSERVATIONAL","A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.",[56],"Oncology","2025-09-26",{"date":59,"type":60},"2025-10-01","ACTUAL",{"date":62,"type":60},"2022-04-06",{"date":64,"type":52},"2028-04-06",{"name":5,"class":6},1]